Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NRG Promethean
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05053152 ↗
- Active, not recruiting
- NRG Oncology
- Focused
We haven't built an HCP commentary report on NRG Promethean (relugolix in oligometastatic prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NRG Promethean so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Oligometastatic Prostate Carcinoma; Prostate Adenocarcinoma; Prostate Ductal Adenocarcinoma; Prostate Intraductal Carcinoma; Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection; Bone Scan; Computed Tomography; Fluciclovine F18; Magnetic Resonance Imaging; Placebo Administration; Positron Emission Tomography; PSMA PET Scan; Relugolix; Stereotactic Body Radiation Therapy
- Arms
- Arm I (placebo, SABR) · Placebo comparator
- Arm II (relugolix, SABR) · Experimental
- Enrollment
- 194 (estimated)
- Primary outcomes
- Radiological progression-free survival (rPFS)
- Sponsor
- NRG Oncology with National Cancer Institute (NCI)
- Start
- Apr 20, 2022
- Primary completion
- Feb 1, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05053152 · updated Aug 17, 2026